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Abstract
The respiratory distress is a very common condition both in term and in preterm neonates 
and the most frequent reason for admission to the neonatal intensive care unit (NICU). 
The aetiology greatly depends on the maturation of neonate’s organs and perinatal 
events. The clinical picture is sometimes scarce and very nonspecific for the etiologic 
determination. Treatment of neonatal RD begins first with the application of a mixture 
of oxygen and air, then with different modes of non-invasive respiratory support meth-
ods. Non-invasive respiratory support can be sustained with nasal continuous positive 
airway pressure, bi-level positive airway pressure and high-flow nasal cannula ventila-
tion. Non-invasive ventilation with high-frequency oscillations through nasal cannula or 
masks is also possible with some respiratory devices. Non-invasive ventilation is usually 
combined with the application of natural surfactant and other therapeutic means, like 
methylxanthine therapy, prevention and closure of patent ductus arteriosus, and control 
of infection. In the case of non-invasive ventilation failure, different kinds of invasive 
ventilation methods are available and being practiced in NICUs. The invasive respiratory 
support can be maintained by controlled or intermittent mandatory ventilation combined 
with different supportive synchronous positive inspiratory ventilation, offered by mod-
ern respirators.
Keywords: neonate, respiration, ventilation, oxygenation, perfusion, evidence-based therapy, 
surfactant, respiratory distress
1. Introduction
The lung is the only organ during foetal development that remains dormant, although foetal 
breathing occurs; gas exchange is performed by the placenta, but the lung is completely ready 
for transition to extra-uterine life. Its development and maturation are precisely regulated 
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during foetal life and needed to accomplish readiness for extra-uterine exchange of gases. 
During labour, different obstetric and non-obstetric factors may affect lung inflation in transi-
tional period to extra-uterine life.
Even mature neonates have smaller diameter of the airways in comparison to infants, chil-
dren and also adults; their chest wall is more compliant and the lung volume at the end 
of expiration is the same as the closing volume. Therefore, their lungs are prone to col-
lapse. Besides, the neonates have fewer alveoli with ventilation perfusion mismatch, but 
a two–three–fold increase in oxygen demand in comparison to adults [1]. They have rela-
tively inefficient respiratory muscles due to lack of red respiratory muscles and more white 
ones, which get tired faster. Their pulmonary vascular wall contains more muscle fibres 
and is therefore more prone to vasoconstriction. The sudden falls in partial oxygen pres-
sure result quickly after short hyperpnoea in hypopnoea or apnoea. The foetal haemoglobin 
binds oxygen with greater affinity than adult haemoglobin. Neonates also have immature 
immune system with lack of the acquired immunity against microorganisms and are thus 
more prone to infection. In a premature infant, all these differences in lung development are 
more prominent in comparison to the term neonate and further influence the transitional 
period of extra-uterine life.
Because of all the above-mentioned developmental immaturity of the lungs, heart, blood ves-
sels, circulation and immune system, neonates are more prone to develop idiopathic respi-
ratory distress (RD) at the beginning of the life but also in later days and weeks and these 
differences are even more pronounced in premature and very premature neonates. The aeti-
ology and pathophysiology of the RD differ between mature and premature infants [2]. In 
the most extreme prematurity, several forms of RD syndrome or hyaline membrane disease 
(HMD) may develop because of lack of surfactant and underdevelopment of the lung.
RD is very common in neonates, affecting about 10% of them [3]. Some of them have disorders 
of transition from foetal to extra-uterine life; others have RD caused by congenital or acquired 
infection or congenital malformations of different organs (thoracic and extra-thoracic). 
Regarding perinatal and labour history, gestational age and appropriateness of birth measures, 
the aetiology of the neonatal RD could be suspected. Clinical picture of neonatal RD is rather 
nonspecific in regard to the aetiology of it and also the management is quite universal. RD may 
develop immediately and acutely after birth or more slowly in the next few hours depending 
on the cause of neonatal breathing difficulties [4].
According to the situation in the delivery room, we have to decide how to approach the neo-
nate with breathing difficulties. A well-equipped and trained neonatology team should be 
available during all difficult or premature deliveries which have to follow recommended 
resuscitation care of the neonate. The first golden minutes are the most important not only 
to properly recognize a neonate who needs our support but also to apply appropriate, suf-
ficient and not too aggressive support if not needed. Appropriate inspiratory pressure and 
oxygen therapy during artificial ventilation in the delivery room may prevent immediate and 
later complications especially in the most vulnerable extreme premature infants. Prevention 
of hypothermia, in premature neonates with plastic bag, is also one of the important prevent-
able methods because it may prevent severe metabolic derangements due to hypothermia, 
harmful for all organs [5].
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2. Methods
We conducted electronic searches of articles on respiratory management and care of neonates 
with RD, using key terms: neonate, respiration, ventilation, oxygenation, oxygen, evidence 
based therapy, caffeine, surfactant, respiratory distress in the PubMed data base from the 
years 2000 to 2017 and reported the most relevant ones. Also, consensus guidelines on neo-
nates with RD were reviewed [6]. The article describes transition from intra- to extra-uterine 
life, lists the methods for assessment of neonates with RD, describes the respiratory support 
in the delivery room, treatment with methylxantines, oxygen and surfactant, and the non-
invasive and invasive tools for artificial ventilation.
This chapter includes the impact of optimal ventilation, tissue oxygenation and perfusion on 
the non-invasive and invasive respiratory management of neonates with RD. Also, the short- 
and long-term outcome in respect of respiratory management of neonates in the neonatal 
intensive care unit (NICU) is addressed.
3. Transition from foetal to extra-uterine life
The transition from foetal to extra-uterine life is a process of rapid physiologic changes in the 
neonate that begin in utero as the foetus prepares for transition from intrauterine placental 
support to extra-uterine self-maintenance. The process can last for up to 12 h after birth and 
depends on the gestational age, placenta, maternal health and congenital anomalies of the 
neonate. The foetus is preparing to the transition by foetal breathing, producing surfactant 
storing glycogen in the liver, producing catecholamines and depositing brown fat. After the 
umbilical cord is cut, placenta no longer does the work of lungs as they begin to exchange 
gasses. The first breath inflates the lungs and causes circulatory changes: the resistance to 
blood flow through lungs falls and more blood flows through pulmonary arteries to the 
lungs. Three foetal shunts close and this results in neonatal circulation. The three processes 
of the transition—(1) the replacement of amniotic fluid in the alveoli with air, (2) the onset of 
regular breathing and (3) the increase in pulmonary blood flow—may all be deranged soon 
after birth and RD ensues [7]. The failure of alveoli fluid clearance results in transient tachy-
pnoea of the newborn (TTN) and causes in turn decreased lung compliance. The deficiency of 
surfactant mainly in preterm neonates or in term infants of diabetic mothers causes collapse 
of the alveoli and diffuse and progressive atelectasis that result in decreased lung compliance 
and small functional residual capacity (FRC) and cause HMD. The abnormal persistence of 
elevated pulmonary vascular resistance either due to underdevelopment, maldevelopment 
or maladaptation of pulmonary vessels results in persistent pulmonary hypertension of a 
newborn (PPHN). PPHN is often associated with congenital anomalies (i.e. congenital dia-
phragmatic hernia) or chronic intrauterine stress (meconium aspiration syndrome (MAS)).
At the time of birth, the umbilical cord is still pulsating. For term and preterm neonates, 
delayed cord clamping is recommended. The preterm neonates born before 32 weeks of gesta-
tion with delayed cord clamping had better neuro-developmental outcomes at the age of 18 
months [8, 9]. Too early umbilical vein clamping, even before the first breath of the neonate, 
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may lead to a prolonged period of low cardiac output, which along with the undeveloped 
self-regulation system leads to a reduction of brain blood flow. Delayed cord clamping allows 
blood to enter the neonate’s circulation and by that enhances the performance of the left ven-
tricle, which is the most important for the normal cardiac output and stable haemodynamics 
especially in foetal distress with compromised haemodynamics at birth [10].
4. Assessment of the respiratory distress of the neonate
The evaluation of a neonate with RD is based on clinical, laboratory and radiologic investiga-
tions. In clinical evaluation, the respiratory effort, breathing efficacy and the breathing effect 
on other organs are assessed (Table 1). Signs of respiratory effort may be less pronounced or 
not visible in three cases: (1) the neonate, who has had RD for a long time, eventually becomes 
tired and signs of respiratory effort are reduced. Tiredness is a pre-terminal sign of respira-
tory failure. (2) A neonate with central nervous depression because of either intoxication, 
or encephalopathy, brain malformation, or increased intracranial pressure, breathes insuf-
ficiently without increased respiratory effort. These neonates breathe insufficiently due to 
reduced breathing impulse. (3) A neonate with neuromuscular disease may have respiratory 
failure without a significantly seen respiratory effort.
Classic laboratory signs of respiratory failure include acidosis (pH < 7.25), hypoxia (PaO
2
 < 
50–60 mm Hg (6.7–8 kPa), FiO
2
 0.6–0.8) and hypercapnia (PaCO
2
 > 60 mm Hg (8 kPa)) which 
are late signs of RD. Radiologically, neonatal chest may be scanned by X-rays [11, 12] or, lately 
more in use, by ultrasound (US) waves [13–17]. In utero, routine foetal US scan following 
development and screening for malformations may reveal intra- or extra-thoracic malforma-
tions, better differentiated by magnetic resonance imaging (MRI). Combining the risk and eti-
ologic factors for neonatal RD, gestational age and radiologic investigations, the pulmonary 
disease causing the RD may be diagnosed (Table 2), since the clinical picture and laboratory 
signs are almost not of any help in defining the aetiology of neonatal RD.
Respiratory effort Breathing efficacy Effect on other organs
1. Breathing rate Chest movement Heart rate
2. Intercostal, jugular, supraclavicular or 
subcostal retractions
Chest auscultation Skin colour: cyanosis, 
paleness, mottled skin
3. Auscultatory phenomena Arterial blood oxygen 
saturation
Disturbance of 
consciousness
4. Feeding difficulties
5. Expiratory grunting
6. Use of auxiliary respiratory muscles
7. Nasal flaring, head nodding
8. Gasping
Table 1. The clinical assessment of airway and breathing in a neonate.
Selected Topics in Neonatal Care48
Pulmonary disease Gestational age, risk 
factors
Aetiology Roentgenogram Ultrasound
Hyaline membrane 
disease
• Preterm
• Neonates of dia-
betic mothers
Lack of 
surfactant
Diffuse reticulogranular 
ground glass pattern 
with air bronchograms 
and small-lung volume; 
grading from mild 
(grade 1) to the most 
severe pattern (grade 4)
Coalescent B-lines-
‘white lung’, thickened 
and irregular pleural 
line
Transitional 
tachypnoea of the 
newborn
• Late preterm
• Elective caesarean 
section
Failure of 
adequate alveoli 
fluid clearance 
at birth
Bilateral perihilar 
linear streaking, patchy 
infiltrates
Compact B-lines in 
the inferior and less 
compact in the superior 
fields (double lung 
point) or bilateral 
numerous noncompact 
B-lines and normal 
pleural line and pleural 
sliding
Persistent pulmonary 
hypertension
• Term > preterm
• Perinatal 
depression
Persistence 
of elevated 
pulmonary 
vascular 
resistance
Clear lung fields with 
decreased pulmonary 
vascularity
Echocardiography
Meconium aspiration 
syndrome
• Term
• Perinatal 
depression
Meconium-
stained amniotic 
fluid
Patchy infiltrates Pulmonary 
consolidation with air 
bronchograms, pleural 
line anomalies, pleural 
effusion, B-lines in non-
consolidation area
Pneumonia Infection of the 
mother
Bacterial or viral 
infection
Non-symmetric bilateral 
patchy infiltrates
Subpleural 
consolidation
Pneumothorax Preterm > term Air entrance 
into the pleural 
space
Edge of collapsed lung Absence of pleura 
sliding and B-lines, 
subpleural consolidation
Congenital heart 
defect
Term > preterm May be diagnostic Echocardiography 
diagnostic
Congenital 
malformation of 
organs
Term>preterm Diagnostic
Metabolic, 
neuromuscular 
diseases
Term > preterm Normal
Genetic defect of 
surfactant proteins
Term, preterm lack of 
surfactant 
proteins
Diffuse reticulogranular 
ground glass pattern 
with air bronchograms 
and small lung volume; 
grading from mild 
(grade 1) to most severe 
(grade 4)
Chronic lung disease of 
different patterns
Table 2. The etiologic and radiologic assessment of respiratory state of a neonate.
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5. Respiratory support in delivery room
Routine care in delivery room depends on whether we expect and take care of extreme pre-
mature neonates or near term or term neonates with breathing difficulties. In case of near 
term or term neonates, care starts with providing warmth, clearing airway if necessary, dry-
ing and stimulating the neonate. Care of preterm infants is different because we immediately 
place him/her into a heated polyethylene bag with small opening for the nose and mouth 
and further stabilize him/her under the heater to assure normal body temperature, prevent 
hypothermia and desiccation [18]. The stabilization of the neonate with RD in the delivery 
room comprises proper head positioning with wiping of the mouth, and rarely, in the case 
of more secretion, not removed by wiping, we may perform gentle suction of the neonate’s 
mouth, then nose. We have to avoid the deep insertion of the catheter and vigorous suctioning 
of mouth which may cause reflex bradycardia. In the case of meconium staining and aspira-
tion, suction of trachea under visual inspection with laryngoscopy guidance is needed first 
and then intubation and further washing out meconium from the trachea. In case of apnoea, 
gasping or bradycardia of <100 beats/minute, it is necessary to ventilate neonate’s lungs with 
positive pressure ventilation considering the use of lowest effective inspiratory pressures and 
volumes to prevent damage to the lungs (barotrauma and volutrauma). Ventilation should 
fill neonatal lung with a gas mixture of air and oxygen. To prevent and reduce the oxidative 
stress, caused by excessive use of oxygen in the inspired air, it is necessary to be careful with 
the use of oxygen. For measuring the arterial oxygen saturation (SpO
2
) in the peripheral blood, 
the pulse oximeter should be attached to the right wrist [19]. Latest guidelines recommend 
starting ventilation of term neonates with FiO
2
 0.21 and later increasing the FiO
2
 according to 
the value of the measured SpO
2
. Ventilation of preterm neonates should be started with FiO
2
 
of 0.21, gradually rising the FiO
2
 in accordance with the measured value of SpO
2
. Ventilation 
of the extremely premature infants (born before 28 weeks gestation) should be started with 
FiO
2
 0.30, while of very premature infants (28–31 weeks of gestation) with the FiO
2
 from 0.21 
to 0.30. If neonate is spontaneously breathing, the constant positive pressure is applied for 
the stabilization of respiration (continuous positive airway pressure) of 6 cm of H
2
O through 
a mask, nasal tubes or endotracheal tube using neonatal respirator (neonatal resuscitator; 
T-piece device), intended for stabilization of the neonate in the delivery room. The maximum 
positive inspiratory pressure should not exceed 20–25 cm H
2
O, which is used only in the 
case of apnoea or bradycardia [6]. No differences in mortality and morbidity of premature 
neonates have been demonstrated in comparing resuscitation starting with low (FiO
2
 ≤0.30) 
or high levels of oxygen (FiO
2
 ≥0.6) [20]. Currently, there is insufficient evidence of sustained 
lung inflation efficacy and safety in the cardiopulmonary resuscitation and stabilization of the 
neonate in the delivery room [21, 22].
6. Methylxanthines
Methylxanthines stimulate the respiratory centre to increase its responsiveness to the partial 
pressure of carbon dioxide in the blood and reduce respiratory depression by hypoxia. They 
also improve respiratory muscle strength. Therapy with caffeine has proven to reduce the 
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duration of artificial ventilation and oxygen demand and decrease risk for bronchopulmo-
nary dysplasia (BPD) and the need for patent ductus arteriosus (PDA) ligation [23, 24]. At 
the age of 2 years, positive effects on cognitive development were observed, but in the same 
group of children at the age of 5 years they were no longer detected [25]. In a premature 
neonate with RD, the less invasive artificial ventilation and surfactant therapy are usually 
combined with early prophylactic intravenous administration of caffeine to achieve the high-
est level of respiratory support in the least invasive form [26, 27]. Since methylxanthines affect 
the diaphragmatic activity and increase the tidal volume, we may use them to increase the 
muscle strength in floppy neonates [28].
7. Treatment with oxygen
Oxygen is necessary for aerobic metabolic processes in the body. The excess of oxygen is 
detrimental to neonates, particularly the premature infants with immature antioxidant, anti-
inflammatory mechanisms and a greater amount of free iron. Hyperoxia affects not only the 
lung but also other organs, with the greatest effects to central nervous system (convulsions) 
and eyes (retinopathy of prematurity (ROP)). In comparison with a ‘higher’ level of SpO
2
 
(91–95%), the ‘lower’ level (85–89%) has been shown to diminish the risk of ROP and BPD, but 
unfortunately at the same time increase mortality, the incidence of necrotizing enterocolitis 
and poor neuro-developmental outcome [29]. Based on research, current recommendations 
propose the SpO
2
 of preterm infants who require oxygen therapy to be between 90 and 94%, 
setting alarm limits to 89 and 95% [6]. The SpO
2
 of term neonates who require oxygen therapy 
should be above 92%.
Hypercapnia is associated with acidosis and compromised cardiovascular function, while 
hypocapnia decreases cerebral blood flow. There is some conflicting evidence on higher PaCO
2
 
levels and the impact on mortality, severe intraventricular haemorrhage (IVH), BPD, ROP and 
neurodevelopmental outcome [30, 31]. Therefore, the optimal target carbon dioxide levels are 
not established; based on available data, it should be between 46 in 60 mm Hg (6.1–8 kPa) for 
ventilated neonates.
Blood gas is monitored in arterial samples, so an indwelling arterial line is necessary in taking 
care of a neonate with moderate or severe RD. Venous and capillary samples are not appropri-
ate for PaO
2
 measurements. They may be of use for PaCO
2
 monitoring, although they slightly 
overestimate it, and pH monitoring, although they slightly underestimate it.
8. Surfactant
Pulmonary surfactant, a macromolecular lipoprotein complex, secreted by the alveolar epi-
thelial cells type II, reduces the surface tension in the pulmonary alveoli at the end of exhala-
tion. Sufficient amount of surfactant in the mature lungs prevents complete collapse of the 
lungs at the end of exhalation. A part of the inhaled air remains to be ‘trapped’ in the pulmo-
nary alveoli, what is called the FRC. In each subsequent breath, it is not necessary to re-open 
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the lungs from the total collapse, which greatly reduces the work of breathing and with that 
fatigue and respiratory failure. A thin layer of a surfactant in the walls of the pulmonary alve-
oli at the end of each inspiration is not completely waterproof, some liquid passes through 
the pores being in contact with the air in the lung alveoli, increasing the surface tension and 
preventing the overdistension of the alveoli at the end of inspiration. The lung surfactant is 
rapidly adsorbed and easily distributed in the form of a thin film on the surface between the 
liquid layer and the air in the lung alveoli [32].
Several animal surfactants of bovine or porcine origin are used in Europe (Table 3).
Currently, a double-blind study of a synthetic surfactant, CHF5633, with the same effect in the 
treatment of RD as poractant alpha, but a stronger anti-inflammatory and a more favourable 
effect on the cerebral haemodynamics, is being conducted [33].
Early publications recommended the application of surfactant in developed RD as a ‘rescue’ 
or therapeutic administration or prophylactically for the prevention of RD in very prema-
ture infants in the first few minutes after birth. Criticism of the prophylactic administration 
of surfactant was that likely 27–60% of preterm infants receive surfactant unnecessarily [34, 
35]. Recommendation nowadays is to stabilize the respiration of a spontaneously breathing 
neonate by using CPAP and early selective surfactant administration. When an endotracheal 
intubation is needed due to progressive RD, the neonate should obtain surfactant as soon as 
possible [6, 36].
Another way of avoiding lung barotrauma and especially volutrauma, techniques to shorten 
the duration of artificial ventilation or even completely avoiding it, has been developed in recent 
years. The first of such methods of fast and non-invasive surfactant application was INtubate—
SURfactant—Extubate (INSURE). The extubation was followed by non-invasive respiratory 
support [37, 38]. In comparing early INSURE method with CPAP without the administration of 
the surfactant, certain advantages were found in the INSURE group. Not enough evidence was 
found to conclude that one of the two methods is better than the other [39].
Type of surfactant Company name Origin of 
surfactant
Lipids (%) Proteins (%) Dose (body mass)
Poractant alfa Curosurf® Extraction from 
porcine lungs
99 SP-B, SP-C
1%
100–200 mg/kg 
(1.25–2.5 ml/kg)
in suspension
Bovactant Alveofact® Lavage from 
bovine lungs
99 SP-B, SP-C
1%
50 mg/kg  
(1.2 ml/kg)
in suspension
Beractant Survanta® Extraction from 
homogenized 
bovine lungs
88–90 SP-B, SP-C
1%
100 mg/kg (4 
ml/kg)
diluted before 
use
Table 3. Surfactants, registered for therapy of RD in Europe.
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Less Invasive Surfactant Administration (LISA) and Minimally Invasive Surfactant Treatment 
(MIST) are other two less invasive methods of surfactant application. With LISA, the preterm 
neonate who is supported by CPAP via nasal prongs, the larynx is opened by laryngoscope 
and by the Magill forceps a thin and soft aspiration tube is inserted below the level of the 
vocal cords, and then the surfactant is applied in two to four aliquots while the neonate is 
spontaneously breathing. With MIST, the tube for surfactant application is somewhat stiffer 
and bent so it can be inserted into the larynx without the Magill forceps. According to the 
authors, MIST is an easier method for less skilled doctors [40]. To confirm the hypothesis 
that less invasive surfactant administration combined with the respiratory support by CPAP 
is more successful in neonates who have some natural surfactant and not effective in those 
who have too little of their own surfactant, a blind, multicentre, randomized study in prema-
ture neonates between 25 and ≤28 weeks gestation, requiring CPAP and a low percentage of 
oxygen in the inhaled air (FiO
2
 from 0.30 to 0.45) during the first 6 h after birth, is currently 
underway. The research group is being treated with poractant alpha at a dose of 200 mg/kg 
body weight, and the control group receives placebo [41]. None of the above-described meth-
ods can avoid laryngoscopy.
The methods of surfactant aerosolization have up to date been more or less unsuccessful. 
With the Catheter And Laryngeal Mask Endotracheal Surfactant Therapy (CALMEST) the 
surfactant is administered by a catheter and the laryngeal mask [42].
The oxygen requirement higher than the FiO
2
>0.3 after 2 h of breathing with CPAP has a 
high positive-predictive value of a respiratory failure at 6 h after birth. Therefore, the recent 
recommendations suggest an early less invasive surfactant administration before the neonate 
requires high proportions of oxygen in the inspired air [43]. If no improvement is seen after 
the first dose, the surfactant application is repeated for the second or third time. In this case, 
the poractant alpha at a dose of 200 mg/kg body weight is supposed to have better effect as a 
lower dose of poractant alpha or beractant (100 mg/kg body weight).
Late-preterm and term neonates besides rarely having a primary surfactant deficiency due to 
genetic defect of surfactant proteins, they more often suffer from secondary surfactant defi-
ciency in conjunction with MAS, pneumonia and pulmonary haemorrhage. In those cases 
small studies have shown improved oxygenation, gas exchange and a reduced need for extra-
corporeal membrane oxygenation (ECMO) [44].
9. Non-invasive respiratory support
The best and most frequently used treatment of neonatal RD nowadays is CPAP through 
nasal spouts (nasal mask, nasal cannula and nasal tube) with the addition of the interfaces 
by using various physical processes to insufflate and exhale the mixture of air and oxygen 
into and out of the respiratory tract of a neonate [45]. It has been proven to reduce side effects 
that neonates could suffer if they were ventilated by the invasive methods of artificial ven-
tilation. Until now, a variety of techniques applying positive pressure of constant pressure 
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(CPAP), the intermittent insufflation of positive pressure (nasal intermittent positive pres-
sure ventilation, NIPPV), which can be time determined or synchronous triggered by 
inhalation (synchronous nasal intermittent positive pressure ventilation (SNIPPV)) and ven-
tilation at two levels of positive pressure (bi-level positive pressure ventilation, Bi-Level) or 
even with high-frequency oscillations (high-frequency oscillation ventilation (HFOV)) have 
been developed. Different randomized studies have explored the advantages or disadvan-
tages of one method of non-invasive ventilatory support over the other. In comparing the 
non-invasive ventilation with NIPPV to the nasal CPAP, fewer respiratory failures and the 
need for intubation in the NIPPV group were found [46]. Meta-analysis of the use of differ-
ent devices and interfaces for CPAP has elucidated differences in outcome depending on 
the use of nasal adapters or interfaces, requiring further research [47]. Similarly, there is an 
open question whether breathing with the help of bi-level CPAP is better than breathing 
with CPAP alone and does it pose an advantage of better exhaling CO
2
, better oxygenation 
or other physiological indicators [48].
If higher mean inspiratory pressures are required for the lungs to remain inflated, the poten-
tial non-invasive ventilation using HFO via nasal tubes or cannulas may be used since even 
long-term studies have confirmed advantages of HFO non-invasive ventilation over other 
invasive ventilation methods.
Ventilation of neonates using high-flow rates (high-flow nasal cannula (HFNC)) has some 
advantages over CPAP due to less damage to the nose and nasal septa and less pneumotho-
rax (PTX) [49]. A multicentre study being conducted in nine centres in Australia and Norway 
might give answers as to which breathing support is better in very preterm infants, CPAP or 
HFNC [50].
Nose requires special attention because the prolonged nasal respiratory therapy may cause 
decubitus and malformations of the nose. Regular changes of devices and protection of the 
nose skin and mucosa with skin-protective strips and/or creams prevent those problems. 
Gastric distension has to be prevented by an opened nasogastric tube and regular checking 
of gastric over distension which decrease compromise of diaphragm contractions. Neonatal 
care in term neutral environment incubators or warm beds and preventive positions like 
Cocoonababy® Nest or similar home-made products besides frequent changes of neonate’s 
positions improve ventilation during the period of acute respiratory problems. Kangaroo 
care is a useful method to improve bonding between the neonate and the mother or father 
but has to be carried out cautiously during non-invasive ventilation [51]. During kangaroo 
care, observations have to be made whether apnoeic spells are more frequent and whether 
bradycardia occurs.
Non-invasive respiratory ventilation enables non-aggressive approaches, without sedation, 
analgesia, tracheal intubation and mechanical ventilation. Complications of non-invasive 
ventilation are mainly pressure sores of skin around the nose, ulceration and necrosis of the 
septum, much less likely hyperinflation of the lungs, restlessness, PTX, stomach distension 
or food intolerance. Non-invasive ventilation failure may be predicted by the use of neonatal 
chest US [52].
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10. Invasive artificial ventilation of the neonate
Nowadays, the invasive artificial ventilation of the neonate represents a continuation of treat-
ment in cases where non-invasive ventilation with or without the use of surfactant is not 
possible or successful. In invasive mechanical support ventilation with a respirator, CPAP is 
usually supplied in combination with intermittent mandatory or synchronized artificial ven-
tilation (i.e. intermittent mandatory ventilation (IMV); synchronized intermittent mandatory 
ventilation (SIMV)). Ventilation can be sustained at two different positive pressure levels (vari-
able/bi-level positive airway pressure, bi-level (BiPAP)). Other forms of artificial ventilation 
include ventilation by releasing the pressure (airway pressure release ventilation (APRV)), 
neuronal-mediated respiratory support (neurally adjusted ventilatory assist (NAVA)), and so 
on. In the case of the artificial ventilation, one should always set the concentration of a mix-
ture of the inspired oxygen and air, the frequency of the ventilation, the ratio of duration of 
the inspiration and expiration or time of inspiration, the end-inspiratory pressure or the tidal 
volume and the end-expiratory pressure. Each respirator is equipped with the heater and 
humidifier in order that neonates breathe moist and warm mixture of air and oxygen. In cases 
of severe pulmonary disease with severe RD, high-frequency oscillating ventilators, which 
use very low inspiratory volumes that do not damage the lung tissue, may be used.
High-frequency oscillation ventilation is a method of artificial ventilation, which in cases of 
severe RD can be the least harmful way of ensuring good oxygenation and due to the active 
exhalation wash out carbon dioxide as well. High-frequency oscillation ventilation will only 
be successful if the pulmonary alveoli are optimally opened prior to the start of oscillations. In 
HFO, the optimization of lung volume is achieved by small increments of continuous positive 
distending airway pressure and the pressure in lung alveoli. Gradually, the increase of con-
tinuous positive distending airway pressure leads to opening of the small, collapsed non-ven-
tilated lung and by that to the increment of the FRC of the lungs that ensure good ventilation 
and oxygenation. Consequently, the optimally opened lung tissue is then oscillated with very 
small tidal gas volume (order of the neonate’s dead space of the lungs), which regulates the 
exhalation of carbon dioxide from the lungs. Oscillations with small volumes are less harmful 
for the delicate lung parenchyma and do not damage it, thereby preventing the secondary 
injury such as barotrauma and volutrauma. When lung function improves, the neonate’s ven-
tilation can be switched to conventional artificial ventilation again [53].
The most important factor in invasive artificial ventilation of the neonate is to prevent the 
lung over-distension, because it injures the delicate lung tissue and causes air leakage outside 
the airway with the development of pulmonary interstitial emphysema (PIE), PTX or pneu-
momediastinum (PM) and other even more severe forms the air leakage into the chest. When 
lungs become more compliant, the pressure-guided artificial ventilation may lead to lung 
over-distension, therefore many of the neonatal respirators are programmed to the restriction 
of tidal volume (volume-targeted ventilation; volume-guaranteed ventilation (VGV)). Care 
should be taken not to cause hypocapnia during ventilation since it decreases the brain blood 
flow and causes periventricular leukomalacia (PVL) and IVH which jeopardize the neurologi-
cal development. The volume-targeted artificial ventilation was shown to shorten the duration 
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of artificial ventilation and hypocapnia, lessen the incidence of BPD, IVH grade III/IV, PTX 
and PVL in comparison to the pressure-controlled ventilation in preterm neonates. The mor-
tality rate was unaffected by the mode of artificial ventilation [54].
During intubation and invasive ventilation, neonates are prone to cardio- and cerebrovascu-
lar instability. The intensive invasive therapy subjects neonates to more infections and the 
invasive ventilation to volu-, barotrauma and shear stress. Common complications due to 
intubations and invasive ventilation are hoarseness, aphonia, tracheal stenosis, and feeding 
and perioral sensation disorders.
11. Additional supportive therapies for neonatal respiratory distress
For treating pulmonary hypertension in different pulmonary diseases of the neonate the 
inhaled nitric oxide, pulmonary artery dilator, has been shown to have some beneficial effects 
[55]. On the other hand it has not been shown to be beneficial in preterm neonates with RD 
in reducing BPD or mortality [56]; though most NICUs are using it nowadays when hypoxic 
respiratory failure in extreme premature cannot be solved by other means [57].
The ECMO pumps the blood through an artificial lung back into the bloodstream, providing 
heart-lung bypass support outside of the neonatal body. ECMO is applied in neonates with 
severe RD due to congenital diaphragmatic hernia (CDH), meconium aspiration syndrome 
(MAS), pneumonia, air leak problems or PPHN [58]. Veno-venous ECMO is preferred to be 
used in infants with hypoxic respiratory failure unless an arterio-venous ECMO is needed 
due to combined cardio-respiratory failure. ECMO support should be used only in neonates 
weighing ≥2 kg of body mass.
General supportive care of a neonate with RD encompasses optimization of thermal neutral 
environment, fluid and nutritional management and a stable hemodynamic state ensuring 
adequate oxygenation and perfusion of neonatal organs.
12. Conclusion
RD of a neonate has almost identical clinical picture irrespective of many etiologic entities it 
originates from. The perinatal history, labour course, the gestational age and appropriateness 
of birth measures for the gestational age should all be taken into account in diagnosing the 
aetiology of the RD.
The modern management of neonatal RD is minimally invasive. In the delivery room, neo-
nates are being stabilized. The respiratory support is primarily non-invasive ventilation as 
well as the surfactant is applied with less invasive methods not involving intubation and 
artificial ventilation. If intubation is required, the time of artificial ventilation should be as 
short as possible. Hyperoxia and hypocapnia should be avoided. Further studies will show 
whether such non-invasive treatment is also going to affect the incidence of BPD, neurodevel-
opmental outcome and other long-term consequences of intensive neonatal therapies.
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